Governance Revolution Medicines, Inc.

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-09 pm EDT			5-day change	1st Jan Change
99.79 ^USD	+1.41%		-1.80%	+25.29%

Mar. 04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
Mar. 03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Executive Committee: Revolution Medicines, Inc.

Manager

Positions heldSince

Mark Goldsmith

64 year

Chief Executive Officer	2014-10-31
Founder	2014-09-30
President	2014-10-31

Jeff Cislini

51 year

General Counsel	2022-08-31
Corporate Secretary	2022-08-31

Wally Reiher

Chief Tech/Sci/R&D Officer

2020-08-31

Wei Lin

64 year

Chief Tech/Sci/R&D Officer

2023-03-31

Peg Horn

63 year

Chief Operating Officer

2018-09-30

Jack Anders

49 year

Director of Finance/CFO

2018-09-30

Luan M. Wilfong

Human Resources Officer

2015-03-04

Steve Kelsey

65 year

Chief Tech/Sci/R&D Officer

2017-02-28

Composition of the Board of Directors: Revolution Medicines, Inc.

Director

CommitteesSince

Mark Goldsmith

64 year

Chairman

2019-12-31

Lorence Kim

52 year

Audit Committee Chair	2023-09-04
Governance Committee Chair
Nominating Committee Chair
Executive Committee	2022-09-30
Compensation Committee
Finance Committee Chair	2022-09-30
Audit Committee	2023-09-30

Elizabeth Anderson

68 year

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee	2019-07-09
Audit Committee	2022-08-31
Compensation Committee	2022-08-31

Alexis Borisy

54 year

Compensation Committee	2015-05-03
Governance Committee
Nominating Committee
Audit Committee	2015-05-03

Sandra Horning

77 year

Governance Committee	2020-11-12
Nominating Committee	2020-11-12

Franklin Clyburn

61 year

Compensation Committee	2024-08-04
Finance Committee

Thilo Schroeder

44 year

Audit Committee

2018-02-28

Flavia Borellini

64 year

Compensation Committee

Sushil Patel

55 year

Audit Committee

2022-06-15

Latest Appointments: Revolution Medicines, Inc.

Jan. 08	PRESS DIGEST-Wall Street Journal - January 8	RE
25-09-29	Revolution Medicines, Inc. Announces Executive Appointments	CI
25-06-18	Revolution Medicines, Inc. Announces Resignation of Barbara Weber as Director, Member of the Board?S Nominating and Corporate Governance Committee and Member of the Board?S Research & Development Committee, Effective June 18, 2025	CI
24-09-16	89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer	MT
24-08-07	Revolution Medicines, Inc. Appoints Frank K. Clyburn, Jr. as Class II Director	CI
23-11-09	Revolution Medicines, Inc. Appoints Sandra J. Horning, M.D., as Member of the Board	CI
23-09-05	Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors	CI

More news

Former Officers and Directors: Revolution Medicines, Inc.

Insider

Positions held

SinceUntil

Barbara Weber

Director/Board Member	2018-03-31	2025-06-17
Independent Dir/Board Member	2018-03-31	2025-06-17

Daniel Simon

Corporate Officer/Principal

2022-08-31

2023-12-31

Eric Schmidt

Director/Board Member	2020-06-16	2023-09-04
Independent Dir/Board Member	2020-06-16	2023-09-04

Neil Exter

Director/Board Member	2019-06-30	2022-07-11
Independent Dir/Board Member	2019-06-30	2022-07-11

Vincent A. Miller

Director/Board Member	2017-08-31	2022-06-15
Independent Dir/Board Member	2017-08-31	2022-06-15

Peter Svennilson

Director/Board Member	2020-06-16	2021-06-21
Independent Dir/Board Member	2020-06-16	2021-06-21

Larry Lasky

Director/Board Member	2016-12-19	2020-06-16
Independent Dir/Board Member	2016-12-19	2020-06-16

Ryan Martins

Director of Finance/CFO

2018-02-28

2018-09-30

Michael Bonney

Director/Board Member

2016-07-31

2017-08-31

Abraham Bassan

Corporate Officer/Principal

2014-11-30

2017-06-30

Kevan Shokat

Founder

2014-09-30

2016-12-17

Michael Fischbach

Founder

2014-09-30

2016-12-17

Martin D Burke

Founder

2014-09-30

2016-12-17

Georgia Erbez

Director of Finance/CFO

2016-04-30

2016-08-31

David Pompliano

Chief Tech/Sci/R&D Officer	2014-09-30	-
Founder	2014-09-30	-

Elaine Heron

Director/Board Member

Carole A. Sable

Chief Tech/Sci/R&D Officer

2015-03-04

Age distribution of managers

Parity Men Women

Male	15
Female	4

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	8
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâ€™s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâ€™s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Employees

883

Sector

Biotechnology & Medical Research

More about the company